Citius Pharmaceuticals updates I/ ONTAK launch progress, shares trade on Nasdaq

Citius Pharmaceuticals provides fresh detail on the commercial rollout of cancer therapy I/ONTAK and keeps investors focused on upcoming catalysts including the planned LYMPHIR and Mino-Lok spinoff.

By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-25, 14:12.

Citius Pharmaceuticals (US1729001026) continues to report on the commercial ramp of its oncology therapy I/ONTAK while preparing for a planned spin-off of its LYMPHIR and Mino-Lok assets. The stock trades on Nasdaq in New York and targets niche markets in hematology and oncology, as the company highlights in recent investor materials. Citius corporate update

What Citius updates on I/ONTAK

Citius Pharmaceuticals Inc. outlined the commercial progress of I/ONTAK (denileukin diftitox-cxdl) for relapsed or refractory cutaneous T-cell lymphoma in a detailed corporate update in May 2026. The company focuses on expanding prescriber adoption in key U.S. oncology centers and building payer coverage for the biologic. Company information on I/ONTAK

The management team stresses that I/ONTAK addresses a rare disease segment where existing treatment options remain limited, pointing to a targeted patient population in the low thousands in the United States. Citius reports that it is increasing its field-based medical affairs presence to support physicians and to educate about the drug's safety and efficacy profile.

Strategy with LYMPHIR and Mino-Lok

Beyond I/ONTAK, Citius plans to separate its LYMPHIR (denileukin diftitox) and Mino-Lok (antibiotic lock solution) programs into a standalone public company to sharpen strategic focus. In its latest shareholder communications, management argues that the transaction could highlight the value of these late-stage assets for investors in both entities. Recent Citius SEC filing

The company reiterates that LYMPHIR aims at peripheral T-cell lymphoma indications, while Mino-Lok is designed for catheter-related bloodstream infections, areas where peers such as Seagen's lymphoma products and various anti-infective regimens set the competitive frame. Citius underscores that it continues to advance regulatory and operational preparations for the spin transaction, including capital structure and governance planning.

The product behind the stock

I/ONTAK is a fusion protein targeting IL-2 receptor positive cells for adults with relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy. The drug is administered intravenously in specialized oncology settings, where Citius supports distribution and medical education.

Where the stock trades today

As of 2026-06-25, 12:00, Citius Pharmaceuticals shares last changed hands on Nasdaq at 0.90 US dollars in relatively modest volume for the session.

Citius Pharmaceuticals at a glance

• Company: Citius Pharmaceuticals Inc.
• ISIN: US1729001026
• WKN: A2DPE8
• Ticker: CTXR
• Trading venue: Nasdaq
• Price (as of 2026-06-25, 12:00): 0.90 USD
• Market cap: 160 million USD (as of 2026-06-25)
• Sector / industry: Health Care / Biotechnology
• Index membership: not part of a major benchmark index
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.